Primary prevention of acute myocardial infarction with aspirin;Prevención primaria del infarto de miocardio con ácido, acetilsalicílico

Medicina Clinica

Volumn 122, Issue 15, 2004, Pages 592-594

  Agustí, Antònia ^a   Diogène, Eduard ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ACUTE HEART INFARCTION; ADULT; AGED; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 2542423585     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13060895     Document Type: Review

References (21)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction and stroke in high patients. BMJ 2002;324:71-86.
3. Fuster V, Cohen M, Halperin J. Aspirin in the prevention of coronary disease. N Engl J Med 1989;321;183-4.
4. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-6.
5. Steering committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' health study. N Engl J Med 1989;321:129-35.
6. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-41.
7. Hansson L, Zanchetti A, Carruthers G, Dahlöf B, Elmfeldt D, Julius S, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
8. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:89-95.
9. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72.
10. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: Recommendation and Rationale. Ann Intern Med 2002;136:157-60.
11. Lauer MS. Aspirin for primary prevention of coronary events. N Engl J Med 2002;346:1468-74.
12. US panel rejects aspirin for primary prevention. Scrip 2003; n.° 2910: 22.
13. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, patophysiology, and management. JAMA 2002;287:2570-81.
14. Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med 2000;342:1040-2.
15. Haffner SM, Lehto S, Rönnemaa, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
16. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2004;27(Suppl 1):72-3.
17. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992;268:1292-300.
18. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, on behalf of the PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Results of the Primary Prevention Project (PPP). Diabetes Care 2003;26:3264-72.
19. American Heart Association. AHA scientific statement: AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 2002;106:388-91.
20. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 2002;105:1620-22.
21. Ceriello A, Motz E. Prevention of vascular events in diabetes mellitus: which «antithrombotic» therapy? Diabetologia 1996;39:1405-6.